Floatz logo

Ramelteon

Bipolar Disorder

TakedaSmall moleculePhase 4 / ApprovedDormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

67 Active assets in the Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LAMOTRIGINE
Johns Hopkins University
Phase 4BBB
CITALOPRAM
University of Texas Southwestern Medical Center
Phase 4BBB
Paroxetine
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Ramelteon is also rated in:

insomniaDormant
CCC
Indicative ·
53 / 100
View asset →
migraine disorderDormant
CCC
Indicative ·
49 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →